Raju S. Kucherlapati Buys 24,625 Shares of Gelesis Holdings, Inc. (NYSE:GLS) Stock

Gelesis Holdings, Inc. (NYSE:GLSGet Rating) Director Raju S. Kucherlapati acquired 24,625 shares of the company’s stock in a transaction on Wednesday, June 15th. The shares were acquired at an average price of $1.95 per share, for a total transaction of $48,018.75. Following the completion of the acquisition, the director now directly owns 90,264 shares in the company, valued at $176,014.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Shares of Gelesis stock traded down $0.05 on Friday, hitting $1.87. 4,875 shares of the company’s stock traded hands, compared to its average volume of 141,053. The company has a current ratio of 1.42, a quick ratio of 1.10 and a debt-to-equity ratio of 3.38. The business’s 50-day simple moving average is $4.47. Gelesis Holdings, Inc. has a 52-week low of $1.60 and a 52-week high of $12.23.

Gelesis (NYSE:GLSGet Rating) last released its earnings results on Thursday, May 12th. The company reported ($0.10) EPS for the quarter. The firm had revenue of $7.51 million during the quarter.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Virtu Financial LLC bought a new position in Gelesis during the first quarter worth $73,000. Charles Schwab Investment Management Inc. bought a new position in Gelesis during the first quarter worth $76,000. Goldman Sachs Group Inc. acquired a new stake in Gelesis in the first quarter worth $103,000. Northeast Financial Consultants Inc acquired a new stake in Gelesis in the first quarter worth $158,000. Finally, Northern Trust Corp acquired a new stake in Gelesis in the first quarter worth $180,000.

About Gelesis (Get Rating)

Gelesis Holdings Inc, a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. The company also provides PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, it offers a product for obesity and overweight and a pipeline with potential therapies for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, type 2 diabetes, and GS500 for Functional Constipation.

Recommended Stories

Want More Great Investing Ideas?

Receive News & Ratings for Gelesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gelesis and related companies with MarketBeat.com's FREE daily email newsletter.